Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Change in Receivables data on file, last reported at -$19.0 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at -$19.0 million, down 90.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.0 million (up 2522.91% YoY), and the FY2025 annual result was $31.0 million, down 8.82% from the prior year.
• Change in Receivables eased to -$19.0 million in Q1 2026 per RARE's latest filing, from $33.8 million in the prior quarter.
• Over five years, Change in Receivables peaked at $33.8 million in Q4 2025 and troughed at -$19.0 million in Q1 2026.
• A 5-year average of $4.8 million and a median of $2.5 million in 2023 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2023: Change in Receivables sank 955.56% in 2022, then soared 7700.0% in 2023.
• A 5-year view of Change in Receivables shows it stood at $9.1 million in 2022, then sank by 108.69% to -$790000.0 in 2023, then surged by 2763.54% to $21.0 million in 2024, then jumped by 60.79% to $33.8 million in 2025, then plunged by 156.16% to -$19.0 million in 2026.
• Business Quant data shows RARE's Change in Receivables at -$19.0 million in Q1 2026, $33.8 million in Q4 2025, and -$5.4 million in Q3 2025.